Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01782963 · OUTCOME

Median Overall Survival

Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) · Source last updated 2018-10-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
years
Interval / dispersion
95% Confidence Interval
Time frame
From the start of treatment until death or until 5 years after the time of disease progression

What was measured

The median overall survival as measured from the start of treatment until the time of death due to any cause.

Analysis population: Median overall survival was not met before the end of follow-up/ data cutoff point because more than half of the participants were still alive.

Groups in this outcome

Treatment Arm

Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age) Consolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15 Lenalidomide Bortezomib Dexamethasone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment Arm50

Reported measurements

Source class 1
Values in years · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment ArmNANot reportedNANAMedian overall survival was not met before the data cutoff point because more than half of the participants were still alive
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Median overall survival was not met before the data cutoff point because more than half of the participants were still alive
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      50
    units
    Participants
description
The median overall survival as measured from the start of treatment until the time of death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age) Consolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15 Lenalidomide Bortezomib Dexamethasone
    id
    OG000
    title
    Treatment Arm
param Type
MEDIAN
population Description
Median overall survival was not met before the end of follow-up/ data cutoff point because more than half of the participants were still alive.
reporting Status
POSTED
time Frame
From the start of treatment until death or until 5 years after the time of disease progression
title
Median Overall Survival
type
SECONDARY
unit Of Measure
years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice